Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;36(1):12-17.
doi: 10.1111/sdi.13115. Epub 2022 Jul 15.

The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review

Riece Koniman  1 , Su Hooi Teo  1 , Manish Kaushik  1 , Chandramouli Nagarajan  2 , Melinda Si Yun Tan  2 , Han Khim Tan  1 , Maria Erika Gapas Ramirez  3 , Cynthia Ciwei Lim  1 ; S.I.N:G.A.P.O.R.E Initiative (Science In Nephrology: Growth And Progress Of Research & Education)
Affiliations

The use of medium cutoff dialyzers in patients with multiple myeloma and acute kidney injury requiring hemodialysis: A systematic review

Riece Koniman et al. Semin Dial. 2023 Jan.

Abstract

Background: Patients with multiple myeloma and high serum levels of circulating free light chains (FLC) have increased risk of acute kidney injury (AKI) secondary to cast nephropathy and is associated with poor survival. Despite removal of FLC by medium cutoff (MCO) dialyzer, the role of MCO hemodialysis (HD) in the treatment of cast nephropathy and its clinical benefits remain unknown.

Methods: A systematic review was conducted to establish the effectiveness of MCO dialyzer and clinical outcomes, compared to other forms of dialyzers in the removal of FLC, in myeloma patients with AKI. The primary outcome was effectiveness of MCO-HD in reducing serum FLC. The secondary outcomes were HD independence, estimated glomerular filtrate rate, mortality rates, length of hospitalization, rebound of serum FLC before the next dialysis, removal of other molecules during dialysis, and adverse events.

Results: We identified three case series, with a total of 17 patients. There were no randomized controlled trials (RCTs) or cohort studies. These case series showed that MCO dialyzer was effective in the removal of FLC and led to a reduction in FLC concentration post-dialysis. The majority of the case series did not have comparator arm and renal and/or other clinical outcomes.

Conclusion: MCO dialyzer appeared to be effective in the removal of FLC based on the existing limited data. However, more data, particularly large-scale RCTs, are needed to assess the use of MCO dialyzer in reducing serum FLC and its effect on clinical outcomes in patients with multiple myeloma and AKI.

PubMed Disclaimer

References

REFERENCES

    1. Dimopoulos MA, Terpos E, Chanan-Khan A, et al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010;28:4976-4984.
    1. Sanders PW. Mechanisms of light chain injury along the tubular nephron. J Am Soc Nephrol. 2012;23(11):1777-1781. doi:10.1681/ASN.2012040388
    1. Hutchison CA, Batuman V, Behrens J, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol. 2012;8(1):43-51. doi:10.1038/nrneph.2011.168
    1. Bladé J, Fernández-Llama P, Bosch F, et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med. 1998;158:1889-1893.
    1. Cazorla Lόpez JM, García García-Doncel A, Naranjo Muñoz J, Villanego Fernández F, Vigara Sánchez LA, Ceballos Guerrero M. Experience of using haemodialysis with medium cut-off dialyser in cast nephropathy. Nefrologia. 2020;40:367-369. doi:10.1016/j.nefroe.2020.06.011

Publication types

LinkOut - more resources